DIRS.INFO The most relevant business & tech news

☆ Three Listed Chinese Firms Used Endangered Animal Parts as Ingredients Report
▼ + stars: | 2023-10-22 | by ( Oct. | At P.M. | ) www.usnews.com time to read: +3 min

In a report published Monday, the London-based Environmental Investigation Agency urged global investors in the three firms - Beijing Tong Ren Tang group, Tianjin Pharmaceutical group and Jilin Aodong Pharmaceutical Group - to divest their stakes. The group said it focused on the pharmaceutical companies because they are publicly listed, and display products that include leopard or pangolin parts on their websites. Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to several emails and calls from Reuters asking for comment. Jilin Aodong Pharmaceutical Group could not be reached for comment. The environmental group said Deutsche Bank, HSBC Holdings, Citigroup and BlackRock did not respond to its queries.

Persons: Andrew Silver, Selena Li SHANGHAI, Beijing Tong Ren Tang, Avinash Basker, Wells, China's, Selena Li, Miyoung Kim, Miral Organizations: Reuters, UBS, HSBC, Environmental Investigation Agency, Tianjin Pharmaceutical, Jilin Aodong Pharmaceutical, TCM, Deutsche Bank, HSBC Holdings, Citigroup, Co, HSBC Global Asset Management Canada, Royal Bank of Canada, BlackRock, Citigroup ， Deutsche Bank, Medical Products Administration, Protection Locations: HONG KONG, London, Beijing, Tianjin, Jilin, BlackRock, Shanghai, Hong Kong

In a report published Monday, the London-based Environmental Investigation Agency urged global investors in the three firms - Beijing Tong Ren Tang group (600085.SS), Tianjin Pharmaceutical group (600329.SS) and Jilin Aodong Pharmaceutical Group (000623.SZ) - to divest their stakes. The group said it focused on the pharmaceutical companies because they are publicly listed, and display products that include leopard or pangolin parts on their websites. Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to several emails and calls from Reuters asking for comment. Jilin Aodong Pharmaceutical Group could not be reached for comment. The environmental group said Deutsche Bank, HSBC Holdings, Citigroup and BlackRock did not respond to its queries.

Persons: pangolin, Seun, Beijing Tong Ren Tang, Avinash Basker, Wells, China's, Andrew Silver, Selena Li, Miyoung Kim Organizations: REUTERS, Rights, UBS, HSBC, Environmental Investigation Agency, Tianjin Pharmaceutical, Jilin Aodong Pharmaceutical, TCM, Deutsche Bank, HSBC Holdings, Citigroup, BlackRock, & Co, HSBC Global Asset Management Canada, Royal Bank of Canada, Citigroup ， Deutsche Bank, Reuters, Medical Products Administration, Protection, Thomson Locations: Lagos, Nigeria, Rights SHANGHAI, HONG KONG, London, Beijing, Tianjin, Jilin, Shanghai, Hong Kong

☆ Ozempic is taking China by storm. Drugmakers are scrambling to boost supplies
▼ + stars: | 2023-06-06 | by ( Laura He | ) edition.cnn.com time to read: +5 min

Hong Kong CNN —Ozempic, originally a medication for treating diabetes, is in high demand worldwide with celebrities and social media users touting it as a miracle drug for weight loss. “This is a wonder drug,” according to a popular series of posts on Xiaohongshu, a Chinese social app similar to Instagram. Soaring pricesThe social media hype was so enormous that Xiaohongshu launched a crackdown in February and deleted more than 5,000 posts sharing weight loss experiences with Ozempic. Fill the shortageThe weight loss drug market in China is expected to boom in the coming years. Novo Nordisk has applied to China’s drug regulator to widen the scope of use for semaglutide, according to the National Medical Products Administration.

Persons: Hong Kong CNN — Ozempic, they’ve, ” Ozempic, Xiaohongshu, Ozempic, Kevin Frayer, hasn’t Organizations: Hong Kong CNN, Daily, First Affiliated, of Sun, University, Novo Nordisk, Tebon Securities, National Medical Products Administration, ., CNN, Huadong, Intellectual, Beijing Intellectual Property Locations: Hong Kong, China, Ozempic, Guangzhou, Shanghai, Hangzhou, Beijing

☆ A stock trader who's returned 2,700% since late-2020 details the chart pattern he uses to rapidly trade risky small caps
▼ + stars: | 2023-05-17 | by ( Laila Maidan | ) www.businessinsider.com time to read: +9 min

Eduardo Briceno uses a few strategies to trade risky small-cap stocks. Eduardo Briceno had always wanted to take up a career in finance or work in the stock market as a broker. He started day trading full-time in 2017 after moving to the US from Venezuela. There aren't as many institutions that trade penny and small-cap stocks regularly compared to larger names, Sykes said. Although the framework is created for penny stocks, Briceno uses it to trade some small caps because he has observed a similar pattern play out within this category.

☆ China approves two domestically developed COVID drugs
▼ + stars: | 2023-01-29 | by ( ) www.reuters.com time to read: 1 min

BEIJING, Jan 29 (Reuters) - China has approved two domestically developed oral medicines for COVID-19 patients with mild symptoms, the National Medical Products Administration said on Sunday. The drugs, used for treating adult patients with mild to moderate COVID-19 infections, have been developed by Simcere Pharmaceutical Group <2096. HK> and a unit of Shanghai Junshi Biosciences Co Ltd (688180.SS), the administration said in a statement on its website. China abandoned its stringent "zero COVID" policy in early December after protests against it, allowing people to travel and the virus to spread rapidly throughout the country, boosting demand for COVID treatments. Reporting by Kevin Yao; Editing by Muralikumar AnantharamanOur Standards: The Thomson Reuters Trust Principles.

HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc (PFE.N) to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in China, three sources told Reuters. In February last year, China approved Paxlovid, which was supposed to be largely available via hospitals, to treat high-risk patients in several provinces. Pfizer last month reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available. A Pfizer spokesperson said the company is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China. That licence does not allow the companies to sell generic Paxlovid in China.

BEIJING, Oct 7 (Reuters) - The mounting economic toll of China's zero-COVID policy is raising investor hopes that Beijing may finally begin laying the groundwork for the tricky epidemiological and political task of shifting course following this month's Communist Party congress. Goldman Sachs analysts predict China will start relaxing the policy in the April-June quarter. China boasts nine domestically developed COVID vaccines approved for use, more than any other country. REUTERS/Aly SongThe authorities have not approved any foreign-made COVID shots. Many countries offer second booster shots.

Search resuls for: "National Medical Products Administration"

7 mentions found